New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma
Pharmacy Times
JUNE 27, 2025
Acalabrutinib had previously received approval in 2017 as a single agent for this same indication. The recent application was granted both priority review and orphan drug designation.
Let's personalize your content